Targeting piRNA-137463 Inhibits Tumor Progression and Boosts Sensitivity to Immune Checkpoint Blockade via De Novo...

Area of Science:

• Oncology
• Molecular Biology
• RNA Biology

Background:

• PIWI-interacting RNAs (piRNAs) play crucial roles in various cancers, but their specific functions in lung adenocarcinoma (LUAD) are not fully understood.
• Elevated piRNA-137463 levels are associated with poor prognosis in LUAD patients, indicating its potential significance in disease progression.

Purpose of the Study:

• To investigate the role of piRNA-137463 in LUAD progression and its impact on cellular functions and the tumor microenvironment.
• To explore the molecular mechanisms underlying piRNA-137463's effects, including its interaction with lncRNAs and its influence on cholesterol metabolism and immune response.

Main Methods:

• Bioinformatic prediction to identify potential interactions between piRNA-137463 and long non-coding RNAs (lncRNAs).
• In vitro experiments to assess the effects of piRNA-137463 inhibition on LUAD cell proliferation, migration, invasion, and T cell cytotoxicity.
• In vivo studies using mouse models to evaluate the therapeutic potential of piRNA-137463 inhibition in suppressing tumor growth, metastasis, and enhancing anti-PD-1 therapy response.

Main Results:

• Inhibition of piRNA-137463 significantly curbed LUAD cell proliferation, migration, and invasion.
• piRNA-137463 inhibition enhanced T cell cytotoxicity via increased IFN-γ secretion, disrupted cholesterol metabolism, and reduced PD-L1 expression in LUAD cells.
• The study identified a regulatory network involving piRNA-137463, lncRNA LOC100128494, and INSIG1, crucial for piRNA-137463's effects in LUAD.
• In vivo, piRNA-137463 inhibition suppressed tumor growth and metastasis and improved LUAD response to anti-PD-1 therapy.

Conclusions:

• piRNA-137463 promotes LUAD progression by reprogramming cholesterol metabolism.
• Targeting piRNA-137463, potentially through AntagopiRNA-137463, offers a novel therapeutic strategy for LUAD.
• The findings highlight piRNA-137463 as a promising target for comprehensive clinical management of LUAD, including combination therapy with immune checkpoint inhibitors.